NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, has announced results from two studies that were featured in oral presentations at the 2013 IMPAKT Breast Cancer Conference. The studies demonstrated that the Prosigna Breast Cancer Prognostic Gene Signature Assay can estimate risk of recurrence (ROR) between five and 10 years after diagnosis in postmenopausal women with hormone receptor-positive HR+, node-positive, and node-negative early-stage breast cancer.
Knowing which women may be at increased risk of developing a late recurrence would enable doctors to identify women who may be good candidates for extended hormonal therapy. Similarly, this test may be helpful for those at low risk to avoid unnecessary treatment extension.
“The Prosigna ROR score can successfully assess the risk for late recurrence in patients with HR+ early-stage breast cancer, and may be used in the future to enable a more informed treatment decision related to the continued use of systemic endocrine therapy,” says Michael Gnant, MD, Professor at the Medical University of Vienna and President of the Austrian Breast & Colorectal Cancer Study Group.
The Prosigna Breast Cancer Prognostic Gene Signature Assay has received a CE mark and is available for use by healthcare professionals in the European Union and Israel; it is not available in North America. The assay runs on NanoString’s proprietary nCounter Analysis system, which offers a reproducible and cost-effective way to profile many genes simultaneously with high sensitivity and precision. The nCounter Analysis System is currently available for “Research Use Only” in North America. Read more about the two studies, “Predicting risk for late metastasis…” and “Comparison of five different scores for the prediction of late recurrence….”
